ArticleDiscover oncology2025
ALOX15B-based efferocytosis clusters: prognostic implications and immune cell infiltration in breast cancer.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
objectiveEfferocytosis, a process of apoptotic cell clearance, is implicated in the initiation and progression of breast cancer. This study aims to construct an efferocytosis-related genetic risk model to evaluate its prognostic value and its association with immune infiltration in breast cancer.
methodsThe expression patterns of efferocytosis-related genes in breast cancer were analyzed, followed by clustering analysis to explore their relationship with tumor immune infiltration across different subtypes. A risk model based on efferocytosis-related genes was developed to predict breast cancer prognosis and assess its correlation with immune infiltration. Using this model, the association between ALOX15B expression and breast cancer survival was evaluated. In Vitro Functional Assays, the biological role of ALOX15B in breast cancer progression was investigated using the following approaches: Cellular Proliferation: MTT assay, EdU incorporation assay, and colony formation assay were performed to assess proliferation in MCF7 and MDA-MB-231 cells. Transwell was used to quantify migratory and invasive. Flow cytometry was conducted to evaluate cell cycle distribution. Western blotting was performed to assess Epithelial-Mesenchymal Transition marker expression.
resultsClustering analysis of the expression of efferocytosis-related genes in breast cancer, Cluster A had a good prognosis and was closely associated with immune cell infiltration. Functional enrichment analysis of the activation and adaptation of immune response in Cluster A clustering may be an important factor in improving breast cancer prognosis. In addition, an immune-related gene risk model was constructed, which was found to be a valid predictor of breast cancer prognosis. Finally, it was highlighted that the expression of ALOX15B inhibited the proliferation, movement, invasion, and DNA replication capability of breast cancer cells. The growth of breast cancer cells was also impeded by ALOX15B, which hindered cell division during the G1 phase. The expression of ALOX15B is associated with the sensitivity of a variety of chemotherapeutic agents.
conclusionEfferocytosis-related models can be used for the assessment of breast cancer prognosis, while the efferocytosis-related gene ALOX15B can affect the migration and invasive ability of breast cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.